Physician profile
Peter B Ojo
NPI 1417154857
$4,963.28
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,476 · 2020: $40.27 · 2021: $113 · 2022: $63.42 · 2023: $125 · 2024: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $270.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,178.62 | 2019 | |
| Haemonetics Corporation | $155.65 | 2019-2022 | |
| Allergan, INC. | $134.22 | 2019-2021 | |
| Baxter Healthcare | $103.17 | 2024 | Perclot |
| Kowa Pharmaceuticals America, INC. | $57.47 | 2022-2023 | Seglentis |
| Ethicon US, LLC | $49.59 | 2021-2024 | Linx Reflux Management System |
| Misonix INC | $46.85 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $34.20 | 2022 | |
| Tela Bio, INC. | $31.05 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Coopersurgical, INC. | $26.53 | 2019 | |
| Davol INC. | $26.16 | 2023 | Phasix Mesh |
| Reprise Biomedical, INC. | $25.26 | 2021 | |
| W. L. Gore & Associates, INC. | $24.84 | 2023 | Gore Enform Preperitoneal Biomaterial |
| Shire North American Group INC | $22.51 | 2019 | |
| Olympus America INC. | $16.45 | 2024 | Endoeye Flex Deflectable Videoscope |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acelrx Pharmaceuticals, INC. | $15.42 | 2019 | |
| Si-Bone, INC. | $15.29 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Ojo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.